This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Dengue Fever Treatment Market

Market Insights on Dengue Fever Treatment covering sales outlook, demand forecast & up-to-date key trends

Dengue Fever Treatment Market by Type, Route of Administration, End User, Region | Forecast 2023 to 2033

Dengue Fever Treatment Market Snapshot (2023 to 2033)

The global Dengue Fever Treatment Market is expected to garner a market value of US$ 877.82 Million in 2023 and is expected to accumulate a market value of US$ 5435.25 Million by registering a CAGR of 20% in the forecast period 2023 to 2033. The market for Dengue Fever Treatment registered a CAGR of 11% in the historical period 2018 to 2022.

Studies state that in 2022, and as of 19 December, 3,766,153 cases and 3582 deaths have been reported. The majority of cases have been reported from Brazil (2,182,229), Vietnam (325 604), Philippines (201,509), India (110,473), and Indonesia (94,355).

Report Attribute

Details

Expected Market Value (2023)

US$ 877.82 Million

Anticipated Forecast Value (2033)

US$ 5435.25 Million

Projected Growth Rate (2023 to 2033)

20% CAGR

Customize this Report

Let us know your requirement to get
100% FREE customization

2018 to 2022 Dengue Fever Treatment Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Dengue Fever Treatment reflected a value of 11% during the historical period, 2018 to 2022.

A series of international-level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering dengue fever treatments. Majority growth is likely to remain concentrated across the Asia-Pacific region, attributed to maximum dengue fever concentration as well as the presence of reputed regional pharmaceutical giants.

In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights into key factors driving demand for dengue fever treatment. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of dengue is fuelling market growth. Thus, the market for Dengue Fever Treatment is expected to register a CAGR of 20% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Dengue Fever Treatment Market?

Increased incidence of Dengue Cases to Push the Market Growth

According to the World Health Organization, the incidence of dengue has grown dramatically over recent decades. A vast majority of the cases are asymptomatic, mild, or self-managed, and hence the actual number of infections is highly under-reported. One modeling estimate indicates 390 Million dengue virus infections per year (95% credible interval 284-528 Million), of which 96 Million manifest clinically.

Another clinical study has established that nearly 4 billion people are at risk of infection. Despite a risk of infection existing in 129 countries, 70% of the actual burden is concentrated in Asia. Furthermore, the number of reported dengue cases over the past two decades has increased eightfold since the past 20 years, from 505,430 cases in 2000 to over 2.4 Million in 2019, with death rates climbing from 960 to 4032.

As of 2020, dengue continues to affect several countries, with the Americas reporting over 3 Million cases out of which 25,000 are classified as severe. High incidences were also reported across Bangladesh (101,000), Malaysia (131,000), the Philippines (420,000), and Vietnam (320,000). Hence, major pharmaceutical giants are accelerating the pace of their ongoing clinical trials, as well as initiating new ones so as to capitalize on this opportunity and expand their presence.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Challenges Faced by the Dengue Fever Treatment Market?

Expensive Cost of Treatment to restrict Market Growth

The expensive treatment of Dengue Fever Treatment, less awareness of Dengue Fever Treatment disease, and insubstantial treatment options are hampering the market growth. Furthermore, lack of health remuneration policies, rise in cost, and side effects associated with certain treatments are expected to hinder the market growth.

Region-Wise Insights

How is the Market for Dengue Fever Treatment Market Turning Out in the Asia Pacific Region?

Improvement in healthcare spending propelling the growth of Dengue Fever Treatment in Asia Pacific

The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Dengue Fever Treatment Market in the region. Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the market worldwide.

India-based Serum Institute initiated a clinical trial in 2017 for verifying the efficacy of its VIS513 monoclonal antibody to treat dengue infections throughout the Indian subcontinent. The company holds exclusive licenses to the treatment for commercialization across all seven countries and has invested a sum of US$ 5 million, which would yield an additional US$ 34 million upon achievement of the set milestone.

Similarly, Sun Pharmaceutical Industries Ltd. has forged a partnership with the International Center for Genetic Engineering and Biotechnology (ICGEB) to develop a dengue vaccine that is safe, effective, and affordable. As per this agreement, Sun Pharma is funding and developing the DSV-4 vaccine candidate that targets all four serotypes of the dengue virus.

What are the Factors Boosting the Market for Dengue Fever Treatment in North America?

Technological Advancements Shaping Landscape for Dengue Fever Treatment in North America

North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region.

According to the Centers for Disease Control and Prevention (CDC), dengue outbreaks occasionally occur in the continental U.S.A. However, these outbreaks are common across its overseas territories, including Puerto Rico, the US Virgin Islands, and American Samoa respectively. On the mainland, outbreaks were frequent across Hawaii (2015), Florida (2013, 2020), and Texas (2013).

Between January 2010 and December 2017, a total of 5,387 dengue cases were reported. The majority of these were associated with travel (5,009; 93%), with the median patient age at 41 years. Over half of the cases (54%) were reported from five states: New York (18%), California (16%), Florida (14%), Texas (5%), and New Jersey (5%). This led to an overall hospitalization rate of 40%.

In May 2019, the US Food & Drug Administration approved the use of Sanofi’s Dengvaxia® live attenuated vaccine which is administered as three separate injections in 9-through-16-year-olds. In addition, existing trials for the ChimeriVaxTM Tetravalent Dengue Vaccine are expected to yield conclusive results in the future, paving the way for the entry of another potential vaccine candidate. Furthermore, due to the presence of leading technological advancements in the healthcare sector and healthcare facilities with the advancements in technology, efficient treatments are being introduced.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Category-Wise Insights

By Type, Which Segment is Likely to Account for a Prominent Share?

Vaccines as an effective treatment to drive the market

Dengue vaccine development has entered an important stage of its life cycle - with a host of pharmaceutical giants expected to present the results of their extensive clinical trials initiated in the past decade or half a decade. Considering these factors, vaccines are considered an effective treatment to account

Presently, Dengvaxia is being marketed by pharmaceutical giant Sanofi Pasteur and has been approved across 19 countries and the European Union. It also gained approval across the USA market in 2019. The vaccine is approximately 76% effective in preventing symptomatic, laboratory-confirmed dengue diseases in 9 through 16 years of age. Simultaneously, several other corporations are developing new vaccine candidates, thus generating immense revenue potential.

By End-user, Which Segment is Likely to Account for a Significant Share?

Hospitals to take the lead and drive market growth

According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during the dengue fever treatment facilitates the growth of this segment. Hospitals are also emphasizing the delivery of various comprehensive programs with personalized and professional support in the management of target diseases.

Start-up Scenario

Key start-up players in the Dengue Fever Treatment Market are-

  • The US-based startup mFluiDx offers a DNA-based diagnostic test. It combines nucleic acid diagnostics with vacuum-based microfluidics technology to enable multi-target testing. As a result of their technology, the diagnostic test offers a low-cost alternative to conventional PCR testing. It is also a highly sensitive and automated point-of-care diagnostic assay for the detection of infectious diseases.
  • Singaporean startup StratifiCare provides a severe dengue prediction kit. It uses a set of proprietary biomarkers and a common laboratory assay platform. The solution is currently in the clinical development stage. The kit is able to deliver accuracy with 90% sensitivity and 97% specificity, in turn, reducing hospitalization costs.

Market Competition

Key players in the Dengue Fever Treatment Market are Mylan N.V, Pfizer Inc., Teva Pharmaceuticals USA, Inc., Perrigo Company plc, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Limited, Fresenius Kabi USA, Sun Pharmaceutical Industries Ltd., ABIVAX, Aurobindo Pharma, Baxter, EMERGEX VACCINES, Hikma Pharmaceuticals PLC, Sanofi, and Takeda Pharmaceutical Company Limited among other global players.

  • In March 2021, Takeda Pharmaceutical Company Limited announced the approval of its TAK-003 dengue vaccine candidate by the European Medicines Agency (EMA), currently under investigation for preventing any outbreaks in individuals aged 4 to 60. The company also intends to apply for regulatory approvals in Argentina, Brazil, Columbia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka, and Thailand through 2021.
  • In December 2021, Kao Corporation announced the launch of a campaign to reduce the spread of dengue fever. Kao used its original technology to develop similar products as part of the initiative. Kao distributed 80,000 units of the product in partnership with the Thai Ministry of Public Health and donated 6.5 Million Thai baht to the Ministry in total, which includes the items. In addition, the initiative enhanced the demonstration and research efforts as well as raised overall awareness of Dengue disease.

Report Scope

Report Attribute

Details

Market Value in 2023

US$ 877.82 Million

Market Value in 2033

US$ 5435.25 Million

Growth Rate

CAGR of 20% from 2023 to 2033

Base Year for Estimation

2022

Historical Data

2018 to 2022

Forecast Period

2023 to 2033

Quantitative Units

Revenue in USD Million and CAGR from 2023 to 2033

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis

Segments Covered

  • Type
  • End-User
  • Route of Administration
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)

Key Countries Profiled

  • The USA
  • Canada
  • Brazil
  • Argentina
  • Germany
  • The United Kingdom
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • Association of Southeast Asian Nations
  • Gulf Cooperation Council
  • South Africa

Key Companies Profiled

Mylan N.V, Pfizer Inc., Teva Pharmaceuticals USA, Inc., Perrigo Company plc, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Limited, Fresenius Kabi USA, Sun Pharmaceutical Industries Ltd., ABIVAX, Aurobindo Pharma, Baxter, EMERGEX VACCINES, Hikma Pharmaceuticals PLC, Sanofi, and Takeda Pharmaceutical Company Limited

Customization

Available Upon Request

Key Segments Profiled in the Dengue Fever Treatment Industry Survey

Type:

  • Drug
  • Vaccines

Route of Administration:

  • Oral
  • Parenteral

End-User:

  • Hospital
  • Homecare
  • Specialty Clinics
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

From 2018 to 2022, the Dengue Fever Treatment Market grew at a CAGR of 11%.

The global Dengue Fever Treatment Market is expected to grow with a 20% CAGR during 2023 to 2033.

As of 2033, the Dengue Fever Treatment Market is expected to reach US$ 5435.25 Million.

According to the FMI analysis, hospitals account for the largest market share.

North America is expected to possess 25% market share for the Dengue Fever Treatment Market.

The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.

Table of Content

1. Executive Summary | Dengue Fever Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033

        5.3.1. Drug

        5.3.2. Vaccines

    5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033

6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Oral

        6.3.2. Parenteral

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-user

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End-user, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-user, 2023 to 2033

        7.3.1. Hospitals

        7.3.2. Homecare

        7.3.3. Specialty Clinics

        7.3.4. Others

    7.4. Y-o-Y Growth Trend Analysis By End-user, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End-user, 2023 to 2033

8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Type

        9.2.3. By Route of Administration

        9.2.4. By End-user

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Type

        9.3.3. By Route of Administration

        9.3.4. By End-user

    9.4. Key Takeaways

10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Type

        10.2.3. By Route of Administration

        10.2.4. By End-user

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Type

        10.3.3. By Route of Administration

        10.3.4. By End-user

    10.4. Key Takeaways

11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Type

        11.2.3. By Route of Administration

        11.2.4. By End-user

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Type

        11.3.3. By Route of Administration

        11.3.4. By End-user

    11.4. Key Takeaways

12. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Singapore

            12.2.1.5. Thailand

            12.2.1.6. Indonesia

            12.2.1.7. Australia

            12.2.1.8. New Zealand

            12.2.1.9. Rest of Asia Pacific

        12.2.2. By Type

        12.2.3. By Route of Administration

        12.2.4. By End-user

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Type

        12.3.3. By Route of Administration

        12.3.4. By End-user

    12.4. Key Takeaways

13. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Type

        13.2.3. By Route of Administration

        13.2.4. By End-user

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Type

        13.3.3. By Route of Administration

        13.3.4. By End-user

    13.4. Key Takeaways

14. Key Countries Analysis

    14.1. USA

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Type

            14.1.2.2. By Route of Administration

            14.1.2.3. By End-user

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Type

            14.2.2.2. By Route of Administration

            14.2.2.3. By End-user

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Type

            14.3.2.2. By Route of Administration

            14.3.2.3. By End-user

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Type

            14.4.2.2. By Route of Administration

            14.4.2.3. By End-user

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Type

            14.5.2.2. By Route of Administration

            14.5.2.3. By End-user

    14.6. UK

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Type

            14.6.2.2. By Route of Administration

            14.6.2.3. By End-user

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Type

            14.7.2.2. By Route of Administration

            14.7.2.3. By End-user

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Type

            14.8.2.2. By Route of Administration

            14.8.2.3. By End-user

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Type

            14.9.2.2. By Route of Administration

            14.9.2.3. By End-user

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Type

            14.10.2.2. By Route of Administration

            14.10.2.3. By End-user

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Type

            14.11.2.2. By Route of Administration

            14.11.2.3. By End-user

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Type

            14.12.2.2. By Route of Administration

            14.12.2.3. By End-user

    14.13. Singapore

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Type

            14.13.2.2. By Route of Administration

            14.13.2.3. By End-user

    14.14. Thailand

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Type

            14.14.2.2. By Route of Administration

            14.14.2.3. By End-user

    14.15. Indonesia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Type

            14.15.2.2. By Route of Administration

            14.15.2.3. By End-user

    14.16. Australia

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Type

            14.16.2.2. By Route of Administration

            14.16.2.3. By End-user

    14.17. New Zealand

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Type

            14.17.2.2. By Route of Administration

            14.17.2.3. By End-user

    14.18. GCC Countries

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Type

            14.18.2.2. By Route of Administration

            14.18.2.3. By End-user

    14.19. South Africa

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2022

            14.19.2.1. By Type

            14.19.2.2. By Route of Administration

            14.19.2.3. By End-user

    14.20. Israel

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2022

            14.20.2.1. By Type

            14.20.2.2. By Route of Administration

            14.20.2.3. By End-user

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Type

        15.3.3. By Route of Administration

        15.3.4. By End-user

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. GeneOne Life Science, Inc

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Johnson & Johnson

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Merck Sharp & Dohme Corp.

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Novartis AG

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Sanofi

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Serum Institute of India Pvt. Ltd

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Sun Pharmaceutical Industries Ltd.

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Takeda Pharmaceutical Company Limited

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Pfizer Inc.

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Teva Pharmaceuticals

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Value (US$ Million) Forecast by Type, 2018 to 2033

Table 3: Global Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 4: Global Value (US$ Million) Forecast by End-user, 2018 to 2033

Table 5: North America Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Value (US$ Million) Forecast by Type, 2018 to 2033

Table 7: North America Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 8: North America Value (US$ Million) Forecast by End-user, 2018 to 2033

Table 9: Latin America Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Value (US$ Million) Forecast by Type, 2018 to 2033

Table 11: Latin America Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 12: Latin America Value (US$ Million) Forecast by End-user, 2018 to 2033

Table 13: Europe Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Value (US$ Million) Forecast by Type, 2018 to 2033

Table 15: Europe Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 16: Europe Value (US$ Million) Forecast by End-user, 2018 to 2033

Table 17: Asia Pacific Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: Asia Pacific Value (US$ Million) Forecast by Type, 2018 to 2033

Table 19: Asia Pacific Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 20: Asia Pacific Value (US$ Million) Forecast by End-user, 2018 to 2033

Table 21: MEA Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: MEA Value (US$ Million) Forecast by Type, 2018 to 2033

Table 23: MEA Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 24: MEA Value (US$ Million) Forecast by End-user, 2018 to 2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Value (US$ Million) by Type, 2023 to 2033

Figure 2: Global Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 3: Global Value (US$ Million) by End-user, 2023 to 2033

Figure 4: Global Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Value (US$ Million) Analysis by Type, 2018 to 2033

Figure 9: Global Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 10: Global Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 11: Global Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 12: Global Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 13: Global Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 14: Global Value (US$ Million) Analysis by End-user, 2018 to 2033

Figure 15: Global Value Share (%) and BPS Analysis by End-user, 2023 to 2033

Figure 16: Global Y-o-Y Growth (%) Projections by End-user, 2023 to 2033

Figure 17: Global Attractiveness by Type, 2023 to 2033

Figure 18: Global Attractiveness by Route of Administration, 2023 to 2033

Figure 19: Global Attractiveness by End-user, 2023 to 2033

Figure 20: Global Attractiveness by Region, 2023 to 2033

Figure 21: North America Value (US$ Million) by Type, 2023 to 2033

Figure 22: North America Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 23: North America Value (US$ Million) by End-user, 2023 to 2033

Figure 24: North America Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Value (US$ Million) Analysis by Type, 2018 to 2033

Figure 29: North America Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 30: North America Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 31: North America Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 32: North America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 33: North America Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 34: North America Value (US$ Million) Analysis by End-user, 2018 to 2033

Figure 35: North America Value Share (%) and BPS Analysis by End-user, 2023 to 2033

Figure 36: North America Y-o-Y Growth (%) Projections by End-user, 2023 to 2033

Figure 37: North America Attractiveness by Type, 2023 to 2033

Figure 38: North America Attractiveness by Route of Administration, 2023 to 2033

Figure 39: North America Attractiveness by End-user, 2023 to 2033

Figure 40: North America Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Value (US$ Million) by Type, 2023 to 2033

Figure 42: Latin America Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 43: Latin America Value (US$ Million) by End-user, 2023 to 2033

Figure 44: Latin America Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Value (US$ Million) Analysis by Type, 2018 to 2033

Figure 49: Latin America Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 50: Latin America Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 51: Latin America Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 52: Latin America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 53: Latin America Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 54: Latin America Value (US$ Million) Analysis by End-user, 2018 to 2033

Figure 55: Latin America Value Share (%) and BPS Analysis by End-user, 2023 to 2033

Figure 56: Latin America Y-o-Y Growth (%) Projections by End-user, 2023 to 2033

Figure 57: Latin America Attractiveness by Type, 2023 to 2033

Figure 58: Latin America Attractiveness by Route of Administration, 2023 to 2033

Figure 59: Latin America Attractiveness by End-user, 2023 to 2033

Figure 60: Latin America Attractiveness by Country, 2023 to 2033

Figure 61: Europe Value (US$ Million) by Type, 2023 to 2033

Figure 62: Europe Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 63: Europe Value (US$ Million) by End-user, 2023 to 2033

Figure 64: Europe Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Value (US$ Million) Analysis by Type, 2018 to 2033

Figure 69: Europe Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 70: Europe Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 71: Europe Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 72: Europe Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 73: Europe Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 74: Europe Value (US$ Million) Analysis by End-user, 2018 to 2033

Figure 75: Europe Value Share (%) and BPS Analysis by End-user, 2023 to 2033

Figure 76: Europe Y-o-Y Growth (%) Projections by End-user, 2023 to 2033

Figure 77: Europe Attractiveness by Type, 2023 to 2033

Figure 78: Europe Attractiveness by Route of Administration, 2023 to 2033

Figure 79: Europe Attractiveness by End-user, 2023 to 2033

Figure 80: Europe Attractiveness by Country, 2023 to 2033

Figure 81: Asia Pacific Value (US$ Million) by Type, 2023 to 2033

Figure 82: Asia Pacific Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 83: Asia Pacific Value (US$ Million) by End-user, 2023 to 2033

Figure 84: Asia Pacific Value (US$ Million) by Country, 2023 to 2033

Figure 85: Asia Pacific Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: Asia Pacific Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: Asia Pacific Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: Asia Pacific Value (US$ Million) Analysis by Type, 2018 to 2033

Figure 89: Asia Pacific Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 90: Asia Pacific Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 91: Asia Pacific Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 92: Asia Pacific Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 93: Asia Pacific Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 94: Asia Pacific Value (US$ Million) Analysis by End-user, 2018 to 2033

Figure 95: Asia Pacific Value Share (%) and BPS Analysis by End-user, 2023 to 2033

Figure 96: Asia Pacific Y-o-Y Growth (%) Projections by End-user, 2023 to 2033

Figure 97: Asia Pacific Attractiveness by Type, 2023 to 2033

Figure 98: Asia Pacific Attractiveness by Route of Administration, 2023 to 2033

Figure 99: Asia Pacific Attractiveness by End-user, 2023 to 2033

Figure 100: Asia Pacific Attractiveness by Country, 2023 to 2033

Figure 101: MEA Value (US$ Million) by Type, 2023 to 2033

Figure 102: MEA Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 103: MEA Value (US$ Million) by End-user, 2023 to 2033

Figure 104: MEA Value (US$ Million) by Country, 2023 to 2033

Figure 105: MEA Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: MEA Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: MEA Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: MEA Value (US$ Million) Analysis by Type, 2018 to 2033

Figure 109: MEA Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 110: MEA Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 111: MEA Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 112: MEA Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 113: MEA Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 114: MEA Value (US$ Million) Analysis by End-user, 2018 to 2033

Figure 115: MEA Value Share (%) and BPS Analysis by End-user, 2023 to 2033

Figure 116: MEA Y-o-Y Growth (%) Projections by End-user, 2023 to 2033

Figure 117: MEA Attractiveness by Type, 2023 to 2033

Figure 118: MEA Attractiveness by Route of Administration, 2023 to 2033

Figure 119: MEA Attractiveness by End-user, 2023 to 2033

Figure 120: MEA Attractiveness by Country, 2023 to 2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Malaria Treatment Market

Published : December 2022

Healthcare

Malaria Ag Rapid Testing Market

Published : September 2021

Healthcare

Anti-Malarial drugs Market

Published : May 2017

Healthcare

Dengue Vaccines Market

Published : April 2021

Google translate

Dengue Fever Treatment Market